JP2019031568A5 - - Google Patents

Download PDF

Info

Publication number
JP2019031568A5
JP2019031568A5 JP2018208158A JP2018208158A JP2019031568A5 JP 2019031568 A5 JP2019031568 A5 JP 2019031568A5 JP 2018208158 A JP2018208158 A JP 2018208158A JP 2018208158 A JP2018208158 A JP 2018208158A JP 2019031568 A5 JP2019031568 A5 JP 2019031568A5
Authority
JP
Japan
Prior art keywords
composition
seq
cdr
antibody
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018208158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019031568A (ja
JP6581279B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019031568A publication Critical patent/JP2019031568A/ja
Publication of JP2019031568A5 publication Critical patent/JP2019031568A5/ja
Application granted granted Critical
Publication of JP6581279B2 publication Critical patent/JP6581279B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018208158A 2013-10-08 2018-11-05 抗ｆｏｌｒ１免疫抱合体投薬レジメン Active JP6581279B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361888337P 2013-10-08 2013-10-08
US201361888365P 2013-10-08 2013-10-08
US61/888,365 2013-10-08
US61/888,337 2013-10-08
US201461948363P 2014-03-05 2014-03-05
US61/948,363 2014-03-05
US201462004815P 2014-05-29 2014-05-29
US62/004,815 2014-05-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016521270A Division JP6463744B2 (ja) 2013-10-08 2014-10-08 抗ｆｏｌｒ１免疫抱合体投薬レジメン

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019156399A Division JP2019218386A (ja) 2013-10-08 2019-08-29 抗ｆｏｌｒ１免疫抱合体投薬レジメン

Publications (3)

Publication Number Publication Date
JP2019031568A JP2019031568A (ja) 2019-02-28
JP2019031568A5 true JP2019031568A5 (https=) 2019-08-08
JP6581279B2 JP6581279B2 (ja) 2019-09-25

Family

ID=52813740

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016521270A Active JP6463744B2 (ja) 2013-10-08 2014-10-08 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2018208158A Active JP6581279B2 (ja) 2013-10-08 2018-11-05 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2019156399A Withdrawn JP2019218386A (ja) 2013-10-08 2019-08-29 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2021125147A Active JP7386208B2 (ja) 2013-10-08 2021-07-30 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2023192883A Pending JP2024016239A (ja) 2013-10-08 2023-11-13 抗ｆｏｌｒ１免疫抱合体投薬レジメン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016521270A Active JP6463744B2 (ja) 2013-10-08 2014-10-08 抗ｆｏｌｒ１免疫抱合体投薬レジメン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019156399A Withdrawn JP2019218386A (ja) 2013-10-08 2019-08-29 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2021125147A Active JP7386208B2 (ja) 2013-10-08 2021-07-30 抗ｆｏｌｒ１免疫抱合体投薬レジメン
JP2023192883A Pending JP2024016239A (ja) 2013-10-08 2023-11-13 抗ｆｏｌｒ１免疫抱合体投薬レジメン

Country Status (29)

Country Link
US (3) US20150132323A1 (https=)
EP (3) EP3653228B1 (https=)
JP (5) JP6463744B2 (https=)
KR (7) KR102303874B1 (https=)
CN (1) CN106164093A (https=)
AU (4) AU2014331964C1 (https=)
BR (1) BR112016007479A2 (https=)
CA (1) CA2926325C (https=)
CY (2) CY1122449T1 (https=)
DK (2) DK3653228T3 (https=)
ES (2) ES2759426T3 (https=)
FI (1) FI3653228T3 (https=)
HR (2) HRP20192140T1 (https=)
HU (2) HUE067367T2 (https=)
IL (4) IL298044B2 (https=)
LT (2) LT3055332T (https=)
MX (2) MX384973B (https=)
MY (1) MY174670A (https=)
NZ (2) NZ757964A (https=)
PL (2) PL3055332T3 (https=)
PT (2) PT3653228T (https=)
RS (2) RS65798B1 (https=)
RU (1) RU2696579C2 (https=)
SG (3) SG10201907042PA (https=)
SI (2) SI3653228T1 (https=)
SM (1) SMT201900694T1 (https=)
UA (1) UA119541C2 (https=)
WO (1) WO2015054400A2 (https=)
ZA (1) ZA201902009B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
IL281714B2 (en) 2011-04-01 2023-11-01 Immunogen Inc Methods for increasing the effectiveness of FOLR1 cancer therapy
HUE049693T2 (hu) 2012-08-31 2020-10-28 Immunogen Inc Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására
CA2911499A1 (en) * 2013-05-14 2014-11-20 Immunogen, Inc. Anti-folr1 immunoconjugate dosing regimens
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
AU2016323968B2 (en) 2015-09-17 2023-07-06 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
RU2019141270A (ru) * 2017-05-16 2021-06-16 Иммуноджен, Инк. Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител
JP7423513B2 (ja) 2017-09-18 2024-01-29 ストロ バイオファーマ インコーポレーテッド 抗葉酸受容体α抗体コンジュゲート及びその使用
CN115925952A (zh) 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
CN112955548B (zh) 2018-07-09 2023-11-24 普众发现医药科技(上海)有限公司 叶酸受体α特异性抗体
WO2020223221A1 (en) 2019-04-29 2020-11-05 Immunogen, Inc. Biparatopic fr-alpha antibodies and immunoconjugates
WO2022256507A1 (en) * 2021-06-04 2022-12-08 Immunogen, Inc. Treatment of cancer in patients with soluble fr-alpha
WO2023102077A1 (en) * 2021-12-01 2023-06-08 Sutro Biopharma, Inc. Anti-folate receptor conjugate cancer therapy
WO2023116911A1 (zh) * 2021-12-24 2023-06-29 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
EP1011694A4 (en) * 1996-11-15 2000-11-15 Baxter Int TREATMENT FOR ALLOGENIC STEM CELL TRANSPLANTATION
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
GB0202319D0 (en) 2002-02-01 2002-03-20 Calex Electronics Ltd Apparatus
WO2004082463A2 (en) * 2003-03-17 2004-09-30 Medical College Of Ohio Folate receptor gene modulation for cancer diagnosis and therapy
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
ATE460668T1 (de) * 2005-03-30 2010-03-15 Purdue Research Foundation Verfahren zur prognose von brustkrebs mittels quantifizierung von zellulären folat vitamin rezeptoren
EP1937307A4 (en) * 2005-09-14 2009-05-13 Hutchinson Fred Cancer Res SPECIFIC REMOVAL OF ACTIVATED IMMUNOCELLS
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2275431A3 (en) 2008-01-18 2011-05-25 Bio-Rad Laboratories, Inc. Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography
WO2009094456A2 (en) * 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
KR20200058590A (ko) 2008-04-30 2020-05-27 이뮤노젠 아이엔씨 가교제 및 그 용도
WO2010080345A1 (en) * 2008-12-19 2010-07-15 Graceway Pharmaceuticals, Llc Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
WO2011050180A1 (en) * 2009-10-21 2011-04-28 Immunogen, Inc. Novel dosing regimen and method of treatment
CN103037900B (zh) * 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
US8530122B2 (en) 2010-07-30 2013-09-10 Konica Minolta Business Technologies, Inc. Foil transferring face forming toner and image forming method
AU2011323124C1 (en) * 2010-11-05 2016-09-22 Eisai Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
IL281714B2 (en) 2011-04-01 2023-11-01 Immunogen Inc Methods for increasing the effectiveness of FOLR1 cancer therapy
US20120282282A1 (en) * 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates
HUE049693T2 (hu) * 2012-08-31 2020-10-28 Immunogen Inc Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására
SG10201903112WA (en) * 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
CA2911499A1 (en) * 2013-05-14 2014-11-20 Immunogen, Inc. Anti-folr1 immunoconjugate dosing regimens
AU2014312086B2 (en) * 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
AU2016323968B2 (en) * 2015-09-17 2023-07-06 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates

Similar Documents

Publication Publication Date Title
JP2019031568A5 (https=)
JP2025129187A5 (https=)
HRP20192140T1 (hr) Režimi doziranja anti-folr1 imunokonjugata
US20250289880A1 (en) Use of anti-fam19a5 antibodies for treating cancers
JP2016534039A5 (https=)
JP2018527383A5 (https=)
RU2018111205A (ru) Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты
RU2019141270A (ru) Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител
AU2018261080A1 (en) Stable formulations of anti-TIGIT antibodies alone and in combination with programmed death receptor 1 (PD-1) antibodies and methods of use thereof
JP2021501776A5 (https=)
IL312038A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2020508317A5 (https=)
JP2020514310A5 (https=)
CN108348521A (zh) 用于治疗癌症的5-溴-2,6-二-(1h-吡唑-1-基)嘧啶-4-胺
FI3394103T3 (fi) Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon
JP2016520082A5 (https=)
JP2017536341A5 (https=)
FI3810281T3 (fi) Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla
KR20160138177A (ko) 항-ｅｇｆｒ 항체 및 항체 약물 접합체
JP2013520442A5 (https=)
JP2010520290A5 (https=)
BR112020016986A2 (pt) formulações de anticorpo contra b7-h4
IL278400B1 (en) Combination of an anti-PD-1 antibody and conjugation of a drug with an anti-TF antibody for use in the treatment of cancer
JP2016525560A5 (https=)
JPWO2018213260A5 (https=)